Is Crop Life Scienc overvalued or undervalued?

As of 6 November 2025, the valuation grade for Crop Life Science has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued based on its key financial ratios, including a PE ratio of 13.98, an EV to EBITDA of 8.16, and a PEG ratio of 1.46. In comparison to its peers, UPL is rated fair with a PE of 41.31, while Bayer CropScience is also expensive with a PE of 36.07, highlighting that Crop Life Science's valuation is significantly lower than these competitors.
Given these metrics and the recent performance, Crop Life Science appears to be overvalued in the current market context. While it has shown a year-to-date return of 7.68%, slightly below the Sensex's return of 7.89%, the overall valuation suggests that investors may be paying a premium for the stock relative to its earnings potential and industry peers.